FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing.
- DOI
- 10.1038/cddis.2015.187
- Published
- 2015 Jul 9
- Container
- Cell death & disease
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/cddis.2015.187,
title = {FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing.},
author = {Wang Z and Dove P and Wang X and Shamas-Din A and Li Z and Nachman A and Oh YJ and Hurren R and Ruschak A and Climie S and Press B and Griffin C and Undzys E and Aman A and Al-awar R and Kay LE and O'Neill D and Trudel S and Slassi M and Schimmer AD},
year = {2015},
journal = {Cell death \& disease},
doi = {10.1038/cddis.2015.187},
url = {https://doi.org/10.1038/cddis.2015.187}
}RIS
TY - JOUR TI - FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing. AU - Wang Z AU - Dove P AU - Wang X AU - Shamas-Din A AU - Li Z AU - Nachman A AU - Oh YJ AU - Hurren R AU - Ruschak A AU - Climie S AU - Press B AU - Griffin C AU - Undzys E AU - Aman A AU - Al-awar R AU - Kay LE AU - O'Neill D AU - Trudel S AU - Slassi M AU - Schimmer AD PY - 2015 JO - Cell death & disease DO - 10.1038/cddis.2015.187 UR - https://doi.org/10.1038/cddis.2015.187 ER -
APA
Z, W., P, D., X, W., A, S., Z, L., A, N., YJ, O., R, H., A, R., S, C., B, P., C, G., E, U., A, A., R, A., LE, K., D, O., S, T., M, S., & AD, S. (2015). FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing.. Cell death & disease. https://doi.org/10.1038/cddis.2015.187
Source records
- pubmed · retrieved 2026-09-26T20:19:40.973Z
- europe-pmc · retrieved 2026-09-26T20:19:40.998Z